Historique
Périodique
A postmarketing surveillance program to monitor Ultram° (tramadol hydrochloride) abuse in the United States
(Programme de surveillance de l'abus de Tramadol aux Etats Unis)
Auteur(s) :
T. J. CICERO ;
E. H. ADAMS ;
GELLER A. ;
J. A. INCIARDI ;
A. MUNOZ ;
S. H. SCHNOLL ;
E. C. SENAY ;
G. E. WOODY
Article en page(s) :
7-22
Refs biblio. :
40
Domaine :
Autres substances / Other substances
Langue(s) :
Anglais
Discipline :
EPI (Epidémiologie / Epidemiology)
Thésaurus mots-clés
SURVEILLANCE EPIDEMIOLOGIQUE
;
MEDICAMENTS
;
ANESTHESIQUES
;
OPIACES
;
ABUS
;
POTENTIEL ADDICTIF
;
EVALUATION
Thésaurus géographique
ETATS-UNIS
Note générale :
Drug and Alcohol Dependence, 1999, 57, (1), 7-22
Note de contenu :
fig., tabl., graph.
Résumé :
FRANÇAIS :
Le Tramadol (Ultram°) est un anesthésique dont le potentiel addictif mérite la mise en place d'un système de surveillance. Des données récoltées sur trois ans ont permis d'évaluer le taux d'abus dans les populations à risque. La majorité des cas d'abus sont dépistés chez des personnes ayant une histoire de toxicomanie, et plus particulièrement chez les utilisateurs de drogues de rue. Le taux reste de l'ordre de un cas pour 100 000 habitants.
ENGLISH :
Trarnadol HC1, marketed as Ultram° in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97%) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pock (Author's abstract.)
Le Tramadol (Ultram°) est un anesthésique dont le potentiel addictif mérite la mise en place d'un système de surveillance. Des données récoltées sur trois ans ont permis d'évaluer le taux d'abus dans les populations à risque. La majorité des cas d'abus sont dépistés chez des personnes ayant une histoire de toxicomanie, et plus particulièrement chez les utilisateurs de drogues de rue. Le taux reste de l'ordre de un cas pour 100 000 habitants.
ENGLISH :
Trarnadol HC1, marketed as Ultram° in the USA, was introduced as a non-scheduled drug in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a non-scheduled status. However, approval was contingent upon the development of an innovative proactive surveillance program, to be overseen by an independent steering committee, which would detect unexpectedly high levels of abuse. The postmarketing surveillance program consisted of systematic collection and scientific evaluation of reports of suspected abuse in high-risk populations surveyed through an extensive key informant network of drug abuse specialists and all spontaneous reports of abuse received through the FDA MedWatch system. Methods to estimate the number of patients prescribed tramadol were also developed. Monthly rates of abuse were calculated as an index of the risk-benefit ratio (i.e., abuse cases per 100 000 patients prescribed the drug). The data for the 3 years since the drug was introduced show that the reported rate of abuse has been low. Although a period of experimentation seemed to occur in the first 18 months after its introduction-which reached a peak rate of approximately two cases per 100 000 patients exposed-during the 2 year period prior to June 1998, the reported rate of abuse has significantly (P=0.011) declined, reaching levels of less than one case per 100 000 patients in the last 18 months. The overwhelming majority of abuse cases (97%) have been found to occur among individuals with a history of substance abuse and the abuse has been confined to isolated pock (Author's abstract.)
Affiliation :
Washington Univ. Sch. Med., 660 S. Euclid Ave, Campus Box 8027, St. Louis MO 63110-1093
Etats-Unis. United States.
Etats-Unis. United States.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |